ASX BRIEFS

Andrew Musgrave
  • 0.0 (0)
  • INVESTING
  • UPDATED DAILY

Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.

  1. 1D AGO

    BRAZILIAN CRITICAL MINERALS LTD (BCM) - BCM’s Ema Project Explained From Giant Clay Resource To Low Cost In Situ Recovery

    Send us Fan Mail A rare earth project that aims to get to production without crushers, grinding circuits, or a high-cost processing maze gets our attention fast. We sit down again with Andrew Reid, Managing Director of Brazilian Critical Minerals (ASX: BCM), to unpack the Ema ionic adsorption clay deposit in Brazil and why in situ recovery (ISR) could be a genuine cost and schedule advantage for a new Western rare earth supply source. We walk through the latest drilling at Ema and what it says about scale and consistency, alongside the updated mineral resource estimate that underpins the move toward a bankable feasibility study (BFS). Andrew explains the vertical profile many clay deposits show, including enrichment toward the base of the clay, and why Ema’s rare earth mix stands out. We also dig into the commercial reality of rare earths: buyers care about the basket, so discussions around neodymium praseodymium and the presence of heavies like dysprosium and terbium can shape offtake interest and downstream pathways. From there, we get practical on execution risk. Andrew shares where the BFS work is focused now, why BCM is doing capital cost estimation in-country in Brazil, and how sourcing standard equipment locally can support credibility. We also cover BCM’s collaboration agreement with an established ISR operator and the strategic tailwinds Andrew is seeing in US-facing conversations about critical minerals and rare earth supply chain security. If you’re tracking ASX rare earth stocks, Brazilian critical minerals, or the path from feasibility to financing, this is a grounded look at what matters next: BFS completion, permitting, offtake, and bankable project funding. Subscribe, share the episode with a mate who follows rare earths, and leave a review with the key risk or catalyst you think will decide the outcome.

    11 min

  2. 3D AGO

    OPTISCAN IMAGING LTD (OIL) - Real-Time Digital Pathology From A Pen-Sized Scanner

    Send us Fan Mail A pen-sized microscope that can see living tissue in real time sounds like science fiction, but it’s exactly what Optiscan Imaging Limited is building. We welcome back Dr Camile Farah to talk through the company’s confocal laser endomicroscopy platform and why real-time digital pathology could change the way surgery, cancer care, and veterinary medicine make decisions at the point of care. We dig into Optiscan’s latest regulatory milestone: the US FDA dossier submission for InSpecta®, a portable veterinary imaging device designed for clinic and field use. Camile explains why the US market matters so much, why veterinary is a smart entry point with a lower barrier than human healthcare, and how that step can de-risk the broader FDA pathway. If you’re tracking ASX medical device stories, this is a clear look at how regulatory strategy links directly to commercial readiness and revenue timing. From there, we move to human health and a world-first in-human head and neck cancer imaging study at St John of God Murdoch Hospital, combining the InVue® precision surgery device with the InForm® Digital Pathology Platform. The core promise is simple and powerful: help surgeons and pathologists assess margins and tissue features in real time, cutting down the anxious wait for lab reports and reducing the risk of a second surgery. We also cover the partnership with Australian Clinical Labs and how telepathology streaming could enable fast expert reads across distance, much like teleradiology did for medical imaging. If you want practical insight into real-time pathology, telepathology, FDA submissions, and the commercial triggers ahead, listen now. Subscribe to ASX Briefs, share the episode with a colleague, and leave a review with your biggest question about live microscopic imaging in theatre.

    9 min

  3. APR 29

    FIREBRICK PHARMA LTD (FRE) - Indonesia’s Approval Signals A Commercial Turning Point For Firebrick Pharma

    Send us Fan Mail A product can be ready for the world and still be held back by one thing: how regulators choose to classify it. We sit down again with Dr Peter Molloy, Executive Chairman of Firebrick Pharma, to unpack the company’s shift from R&D to commercial execution and why a single regulatory milestone in Indonesia changes the scale of the Nasodine opportunity. Peter walks us through the origin story that starts with Betadine and leads to Nasodine, a povidone-iodine nasal spray designed to target the viral cause of the common cold using a topical antiseptic approach. We dig into why povidone-iodine remains compelling after decades of use, how low concentrations can still be potent, and why the “no resistance” profile matters when consumers are surrounded by symptom-only OTC options. Just as importantly, we talk about the practical reality for ASX health companies: Australia’s TGA can treat products like Nasodine as a drug, while markets such as Singapore may treat it as an antiseptic, dramatically changing time, cost, and pathway to market. From there, the conversation turns to growth: Indonesia’s approval and its 60 to 65 million middle and upper-middle class consumers, the Philippines as the next potential major approval, and plans to broaden the Nasodine product range. We also cover the business model behind the strategy, including licensing partnerships that reduce manufacturing and marketing burden, recent capital raising, cash burn, and what “runway” looks like in a tough funding environment. If you’re following Firebrick Pharma, Nasodine, or healthcare commercialisation in Southeast Asia, this is the roadmap and the reality check. Subscribe for more ASX Briefs, share this with a mate who follows biotech, and leave a review with your biggest question about Nasodine’s path to global markets.

    17 min

  4. APR 27

    RADIOPHARM THERANOSTICS LTD (RAD) - When Earlier Detection Becomes Better Survival

    Send us Fan Mail A scan that finds brain metastases earlier could change the whole treatment timeline, and that is exactly what we dig into with Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. We walk through how a clinical-stage ASX biopharmaceutical company designs radiopharmaceuticals for oncology, and why “theranostics” is more than a buzzword when patients need faster, clearer answers.  Riccardo breaks down the company’s two-platform approach: small molecules for imaging that can penetrate tissue and light up tiny tumours, and larger antibody-based therapies that stay in the body long enough to deliver a targeted radioactive payload. We talk about RAD 101 and its interim Phase 2B results in recurrent brain metastases, including strong concordance with MRI and the bigger goal of proving clinical value by detecting more disease earlier. Earlier detection can mean earlier treatment, which can ultimately mean better outcomes.  We also cover the first patient dosed in the Phase 1 RAD 404 study for advanced prostate cancer, using a Terbium‑161 radio labelled antibody designed to damage cancer cell DNA. From there, we zoom out to the broader pipeline, including ongoing Australian studies such as RAD 202 and RAD 204 across lung and breast cancers, and how the team thinks about prioritisation when multiple trials are running at once. Finally, we look at next steps towards a pivotal Phase 3 program, FDA alignment, and what fast track designations could mean as the company moves towards late-stage registrational pathways.  If you found this useful, subscribe for more ASX biotech conversations, share the episode with a mate, and leave a review so more people can find the show.

    7 min

  5. APR 26

    AMPLIA THERAPEUTICS LTD (ATX) - Narmafotinib And Pancreatic Cancer Progress

    Send us Fan Mail Five complete responses in advanced pancreatic cancer should make anyone in biotech sit up. We’re joined by Dr Chris Burns, CEO and Managing Director of Amplia Therapeutics, to unpack what the latest mature ACCENT trial data really says about narmafotinib when it’s added to standard chemotherapy with gemcitabine and Abraxane and why “making other drugs work better” is more than a slogan when patients are running out of time. We talk through the headline numbers, including an 11.1 month median overall survival signal and what “complete response” means in practical clinical terms. Just as important, we dig into tolerability: the combination appears to keep the side effect burden largely in line with chemotherapy alone, which is critical for any add on cancer therapy hoping to move into larger, registration enabling studies. We also explore how the US FDA fast track designation helps shape timelines and strengthens discussions with potential partners watching the pancreatic cancer pipeline closely. Not every combo is worth forcing, and are transparent about that. We cover the recruitment halt in the AMPLICITY trial pairing narmafotinib with the more aggressive FOLFIRINOX regimen, why the limiting toxicity was linked to the chemotherapy, and how the broader landscape is shifting toward targeted and personalised medicines, including emerging RAS inhibitors. We finish with the commercial foundations, from key patents extending protection to at least 2040 in major markets to the next 12 months of milestones across pancreatic and ovarian cancer. If you want clear, investor friendly context on pancreatic cancer drug development, clinical trial readouts, FDA pathways, and partnering strategy, hit play. Subscribe, share this with someone following oncology breakthroughs, and leave us a review with the one result you’ll be watching next.

    15 min

  6. APR 23

    SOLIS MINERALS LTD (SLM) - A 93,000 Hectare Lithium Bet Next Door To A Major Discovery

    Send us Fan Mail A junior explorer doesn’t often get the chance to step into prime ground that’s already been stress-tested by a major miner, right in the middle of a proven hard-rock lithium district. That’s why we sat down with Mitch Thomas, CEO of Solis Minerals, to unpack Solis’ strategic acquisition from Rio Tinto in Brazil’s Lithium Valley and what a 93,000 hectare land position can really mean when the targets are already defined and the plan is to drill. We talk through the story behind the deal, including why this particular concession package is so compelling, how it sits in a region the team knows intimately, and how Solis’ history of building a lithium discovery next door shapes their technical approach today. Mitch explains what makes the early indicators worth chasing, from high lithium soil results to spodumene pseudomorphs, and why Rio Tinto’s extensive groundwork may give Solus a head start as it moves from surface work into scout drilling. Lithium isn’t the only pillar. We also dig into Solis’ Peru copper portfolio, how the company thinks about copper porphyry exploration alongside lithium, and why operating across two in-demand energy metals can support more consistent market updates. Mitch also shares why Solis moved to an Australian-registered structure, what it means for ASX investors in terms of governance and liquidity, and the milestones to watch as the company targets drilling around mid-2026. If you follow lithium exploration, Brazil mining projects, ASX resource stocks, or copper growth stories, hit subscribe, share this episode with a mate, and leave us a review so more investors can find the conversation.

    10 min

  7. APR 20

    VBX LIMITED (VBX) - How VBX Plans A Low-Cost Bauxite Operation In Northern WA

    Send us Fan Mail Guinea supplies a huge share of the traded bauxite market and that concentration is forcing buyers and investors to rethink supply security. We sit down with Ryan De Franck, Managing Director of VBX Limited, to unpack why the Wuudagu Bauxite Project in Western Australia’s North Kimberley could stand out in the global bauxite landscape through a simple idea: pair high-grade, low-silica bauxite with logistics that are short, efficient, and built around real customer needs.  We talk through what makes Wuudagu strategically significant, from its proximity to the coast and protected sea conditions for transshipment, to the shipping advantage of being closer to key end-user regions such as China, India, and the Middle East. Ryan also explains the impact of VBX’s 108% lift in Measured and Indicated Mineral Resource to 131.9 million tonnes, and how that larger, higher-confidence base supports a bigger development case as the Definitive Feasibility Study progresses.  Metallurgy gets a spotlight too, with recent test work indicating a 23% increase in mass recovery versus prior assumptions, and what that can mean for operating costs, profit margins, and payback timing if it carries through at scale. We finish with the execution roadmap: the DFS timeline toward mid-2026, a pathway to first production in 2027, and the near-term milestones that matter most, including traditional owner agreements, approvals, and definitive off-take and funding work with strategic partners.  If you follow ASX mining, bauxite projects, aluminium supply chains, or energy transition materials, this is a sharp update you’ll want in your queue. Subscribe to ASX Briefs, share this episode with a mate watching the sector, and leave a review telling us which milestone you think will be the biggest value driver.

    5 min

  8. APR 19

    AUDEARA LTD (AUA) - Audeara’s CEO Explains The Strategy Behind Q3 Growth

    Send us Fan Mail A kid can’t learn well if the world sounds muffled, painful, or simply out of reach. We’re joined by Dr James Fielding, Managing Director and CEO of Audeara Limited, to talk through a pivotal stretch for this ASX-listed hearing health technology and audio technology company, following strong Q3 FY26 results and a growing global footprint. We start with what Audeara actually builds: hearing health tech solutions sold as Audeara-branded hardware, plus the AUA Technology platform that can power other brands. James then explains the significance of an exclusive agreement with ShokzHear, the global leader in bone conduction listening devices. The goal is practical and urgent: create an optimised listening option for children dealing with chronic ear infections, particularly in regional and remote communities where in-ear devices can be uncomfortable or unusable. We also discuss just how widespread classroom listening issues can be and what better audio access could mean for learning outcomes. From there we dig into the numbers investors care about, including back-to-back positive net operating cash flow and accelerating Australian wholesale revenue, supported by closer partner execution with audiology groups such as Amplifon. We finish with Audeara’s Auracast™ momentum, the Clinico partnership in Taiwan, and the BT-03 Audio Broadcaster rollout into environments like universities, hospitals, government buildings, and even sports bars where people can choose exactly what they want to hear. If you’re tracking ASX small caps, medtech commercialisation, Auracast, bone conduction, or accessible audio, hit subscribe, share this with a mate, and leave a review to help more people find the show.

    11 min
See All (212)

About

Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.

Information

  • Creator
    Andrew Musgrave
  • Years Active
    2024 - 2026
  • Episodes
    212
  • Rating
    Clean
  • Copyright
    © 2026 ASX BRIEFS
  • Show Website
    ASX BRIEFS

You Might Also Like